Horizon Therapeutics PLC (HZNP) Shares Bought by SG Americas Securities LLC
SG Americas Securities LLC raised its stake in Horizon Therapeutics PLC (NASDAQ:HZNP) by 107.7% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 19,606 shares of the biopharmaceutical company’s stock after purchasing an additional 10,168 shares during the period. SG Americas Securities LLC’s holdings in Horizon Therapeutics were worth $518,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its holdings in Horizon Therapeutics by 2.6% in the third quarter. Bank of New York Mellon Corp now owns 863,146 shares of the biopharmaceutical company’s stock valued at $16,900,000 after buying an additional 21,982 shares during the last quarter. Teachers Advisors LLC increased its holdings in Horizon Therapeutics by 1.4% in the third quarter. Teachers Advisors LLC now owns 1,208,358 shares of the biopharmaceutical company’s stock valued at $23,660,000 after buying an additional 16,484 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Horizon Therapeutics by 17.6% during the third quarter. Legal & General Group Plc now owns 67,632 shares of the biopharmaceutical company’s stock worth $1,325,000 after purchasing an additional 10,121 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in shares of Horizon Therapeutics by 631.9% during the fourth quarter. Meeder Asset Management Inc. now owns 9,947 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 8,588 shares during the last quarter. Finally, James Investment Research Inc. purchased a new position in shares of Horizon Therapeutics during the fourth quarter worth about $1,073,000. 85.98% of the stock is owned by institutional investors.
In other news, EVP Geoffrey M. Curtis sold 10,080 shares of the stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $21.21, for a total transaction of $213,796.80. Following the completion of the sale, the executive vice president now owns 35,367 shares in the company, valued at $750,134.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is currently owned by corporate insiders.
Shares of HZNP traded up $0.65 during mid-day trading on Friday, hitting $25.25. 10,552 shares of the company’s stock were exchanged, compared to its average volume of 1,778,305. Horizon Therapeutics PLC has a fifty-two week low of $15.32 and a fifty-two week high of $29.44. The company has a market capitalization of $4.62 billion, a price-to-earnings ratio of 13.79 and a beta of 1.09. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.68 and a current ratio of 1.74.
Horizon Therapeutics (NASDAQ:HZNP) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.20. Horizon Therapeutics had a net margin of 3.79% and a return on equity of 33.57%. The business had revenue of $280.00 million during the quarter, compared to the consensus estimate of $238.35 million. During the same quarter in the prior year, the firm earned $0.03 earnings per share. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. Equities research analysts forecast that Horizon Therapeutics PLC will post 1.64 EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://theolympiareport.com/2019/05/24/horizon-therapeutics-plc-hznp-shares-bought-by-sg-americas-securities-llc.html.
Horizon Therapeutics Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Story: What causes a recession?
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.